Lupus, a chronic autoimmune disease, has long been a challenging condition to manage, often requiring treatments that come with severe side effects and necessitate lifelong administration. However, recent advancements in Chimeric Antigen Receptor (CAR) T cell therapies are providing new hope for
The University of Chicago Medicine (UChicago Medicine) has initiated a Phase 2 clinical trial to explore the potential of CAR T-cell therapy in treating three challenging autoimmune diseases: systemic lupus erythematosus, inflammatory myositis, and systemic sclerosis. CAR T-cell therapy, originally
A phase 1 clinical trial has brought new hope for patients with B-cell lymphoma, a type of blood cancer, through an innovative cell-based immunotherapy. Researchers from Washington University School of Medicine in St. Louis, along with other collaborators, have explored the safety and potential
Gene therapy, a revolutionary approach to treating and preventing diseases by modifying faulty genes, relies heavily on accurate measurement techniques. Ensuring the safety and efficacy of these treatments necessitates precise quantification of adeno-associated virus (AAV) vectors, which deliver
Adicet Bio is pioneering significant developments in its innovative CAR T-cell therapy, ADI-001, aimed at treating a range of autoimmune diseases. Among the targeted conditions are ANCA-associated vasculitis (AAV), systemic lupus erythematosus (SLE), and systemic sclerosis. Initially, patient
Aspect Biosystems, a pioneer in the field of bioprinted tissue therapeutics, recently closed a $115 million Series B financing round aimed at advancing its groundbreaking technology in regenerative medicine. This achievement, led by Dimension and supported by investors such as Novo Nordisk and
